Drug eluting balloon; a valid alternative to treat in-stent restenosis in the superficial femoral artery

Original title: Drug-Eluting Balloon for Treatment of Superficial Femoral Artery In-Stent Restenosis Reference: Eugenio Stabile et al. Journal of the American College of Cardiology 60:1739–42 (2012)

Drug eluting balloon; a valid alternative to treat in-stent restenosis in the superficial femoral artery 

This prospective registry included 39 patients who received Paclitaxel-Eluting Balloon Angioplasty, (IN.PACT, Medtronic, Minneapolis, Minnesota), for in-stent restenosis in the superficial femoral artery. The average length treated was 82.9 + / – 78.9 mm, this required the use of two eluting balloons per patient. The distal protection filter type was used in all cases. Procedure was successful in all patients. At one year follow-up, 92.1% were free of claudication and there was an absence of restenosis by Doppler.

Conclusion: 

Pharmacological balloons are effective in treating in-stent restenosis in the superficial femoral artery.

Editorial comment

This study, which has a lack of control group limit and a small number of patients, shows encouraging results that should be confirmed by randomized studies against the conventional balloon. Particularly striking was the use of a distal protection filter which added to the cost of eluting balloons, making it very difficult to use in practice.

Dr. Gustavo Hidalgo

More articles by this author

A New Asymptomatic Carotid Stenosis Paradigm? CREST-2 Trial Unified Results

Severe asymptomatic carotid stenosis continues to be controversial seeing the optimization of intensive medical therapy (IMT) and the availability lower periprocedural risk revascularization techniques....

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

Hypertriglyceridemia as Key Factor to Abdominal Aortic Aneurysm Development and Rupture: Genetic and Experimental Evidence

Abdominal aortic aneurysm (AAA) is a deadly vascular disease with no effective drug treatment, and risk of rupture reaching up to 80%. Even though...

Atrial Fibrillation and Chronic Kidney Disease: Outcomes of Different Stroke Prevention Strategies

Atrial fibrillation (AF) affects approximately 1 in every 4 patients with end-stage renal disease (ESRD). This population carries a high burden of comorbidities and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...